STOCK TITAN

Verastem (VSTM) CEO sells 393 shares tied to RSU vesting

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Verastem, Inc. reported that its President and CEO, who also serves as a director, carried out a small sale of company stock. On 12/16/2025, the executive sold 393 shares of Verastem common stock at a price of $9.14 per share. According to the filing, this sale was made to satisfy statutory withholding requirements related to the vesting of restricted stock units, meaning it was tied to equity compensation rather than an open-market portfolio decision. After this transaction, the executive still beneficially owns 410,425 shares of Verastem common stock, held directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Paterson Dan

(Last) (First) (Middle)
C/O VERASTEM, INC.,
117 KENDRICK ST., SUITE 500

(Street)
NEEDHAM MA 02494

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Verastem, Inc. [ VSTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/16/2025 S 393(1) D $9.14 410,425 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
/s/ Daniel Calkins, Attorney in Fact 12/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Verastem (VSTM) disclose in this Form 4?

Verastem disclosed that its President and CEO, who is also a director, sold 393 shares of common stock on 12/16/2025 at $9.14 per share.

Why did the Verastem (VSTM) CEO sell 393 shares?

The filing states that the 393-share sale was made to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.

How many Verastem (VSTM) shares does the CEO own after this transaction?

Following the reported transaction, the executive beneficially owns 410,425 shares of Verastem common stock, held in direct ownership.

What was the sale price for the Verastem (VSTM) CEO’s shares?

The 393 shares of Verastem common stock were sold at a price of $9.14 per share on 12/16/2025.

Is this Verastem (VSTM) Form 4 filed by more than one reporting person?

No. The document indicates that the Form is filed by one reporting person, not by a group.

What is the Verastem (VSTM) executive’s role mentioned in this filing?

The reporting person is identified as both a Director and an Officer, serving as President and CEO of Verastem, Inc.

Verastem

NASDAQ:VSTM

VSTM Rankings

VSTM Latest News

VSTM Latest SEC Filings

VSTM Stock Data

583.73M
70.84M
0.82%
89.08%
25.94%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEEDHAM